PDCD1 and melanoma: To evaluate if the PD1+ EVs may cause unresponsiveness to anti-PD1, we performed in vitro experiments to evaluate if they were involved in the seizure of the therapeutic monoclonal antibodies nivolumab and, if the circulating EVs impacted on immune cells-mediated killing of melanoma spheroids, to demonstrate that they are mediators of treatment failure.